Some visit links earn us a commission.

Express Scripts drops Zepbound KwikPens and vials for 2027

By John Samaras, price analyst · Prices checked Nov 16, 2026

Read November 15, 2026 on express-scripts.com

The 2027 Express Scripts National Preferred Formulary excludes Zepbound KwikPens and Zepbound vials. For weight loss it names Zepbound pens, Wegovy pens, Wegovy HD, Wegovy tablets, Foundayo and liraglutide as the preferred alternatives.

What it costs without insurance

If your plan says no

Who this affects

Members whose employer, union or health plan uses the Express Scripts National Preferred Formulary and covers weight-loss drugs. Express Scripts says not every plan covers every drug on the list, so your own benefit papers decide.

When it starts

The exclusions are for the 2027 formulary year. A plan that runs on the calendar year starts it on January 1, 2027.

If you lose coverage: cash now

Two cash programs to check.

No insurance needed.

Prices checked Nov 16, 2026.

  1. Eden$99 a monthIncludes medication, provider review and shippingcompounded semaglutidecompounded tirzepatide $129 a month
    Check price →Eden's GLP-1 page, then an online assessment
  2. Collective$59 a month, drug pricecompounded semaglutidecompounded tirzepatide $69 a month
    Check price →

Zepbound KwikPen 2027: which plans drop it

  • Express Scripts National Preferred Formulary: KwikPens and vials excluded. Zepbound pens stay preferred.
  • Optum Rx Premium Standard Formulary: KwikPens and vials excluded. The Zepbound auto-injector sits at Tier 2 with prior authorization.

Paying for the KwikPen yourself? Zepbound KwikPen cash prices by dose.

What the Express Scripts exclusion list says

Weight Loss. Excluded medications: ZEPBOUND KWIKPENS, ZEPBOUND VIALS. Preferred alternatives: liraglutide, FOUNDAYO, WEGOVY HD, WEGOVY PENS, WEGOVY TABLETS, ZEPBOUND PENS.
  • Brand Saxenda is on the same 2027 list, marked as a brand whose generic is covered, so generic liraglutide stays on the formulary.
  • The list asks members on an excluded drug to have their prescriber consider a new prescription for a preferred alternative.
  • A prescriber who sees a clinical reason to stay on an excluded drug can ask for a coverage review at esrx.com/PA.
  • Express Scripts says costs for covered alternatives vary and points members to express-scripts.com/covered to compare them.

Sources:

What to do before January 1

  • Call the number on your prescription card and ask whether your 2027 plan uses the National Preferred Formulary.
  • If you fill Zepbound KwikPens or vials, ask your prescriber's office before January about a preferred pen or a coverage review.
  • If your plan will not pay, compare the cash routes on this page.

Zepbound vial prices from LillyDirect. Employers dropping GLP-1 coverage in 2027.

What cash costs today

Compounded semaglutide and tirzepatide are pharmacy-made versions that are not Wegovy, Ozempic, Zepbound or Mounjaro.

Compounded prices are the monthly drug price at the lowest-priced program. Any membership is listed on that program's own page.

Buying cash in late November? GLP-1 Black Friday and Cyber Monday offers shows each program's 30-day low and high.

Frequently asked questions

Are Zepbound pens still covered by Express Scripts in 2027?
Zepbound pens are on the preferred side of the 2027 National Preferred Formulary exclusion list. Only Zepbound KwikPens and vials are excluded. Your plan still decides whether it covers weight-loss drugs at all.
Is Wegovy preferred on Express Scripts in 2027?
Yes. Wegovy pens, Wegovy HD and Wegovy tablets are all named as preferred alternatives for weight loss on the 2027 list.
Can I stay on Zepbound vials with Express Scripts?
Only through a coverage review your prescriber requests at esrx.com/PA, which Express Scripts allows when there is a clinical reason. Otherwise the vials are not covered on this formulary in 2027, and you can still buy them for cash.

Cash does not go through your plan and does not count toward its deductible. Federal plan GLP-1 changes for 2027. GLP-1 coverage by payer.